TARA News

Protara Therapeutics, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Protara Therapeutics to Present Updated Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in BCG-Unresponsive NMIBC Patients at the ASCO Genitourinary Cancers Symposium

TARA Media, SWYM.ai Bring AI-Powered Supply Shaping to Media Buying Platform

Telecom Site Management Software Market to Surpass USD 792.48 Million by 2033, Driven by 5G Expansion and Growing Tower Deployments | Research by SNS Insider

Protara Therapeutics Highlights Recent Updates and Anticipated 2026 Milestones

Protara Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Protara Therapeutics Announces Dosing of First Patient in Phase 3 Registrational THRIVE-3 Trial of IV Choline Chloride in Patients on Long-Term Parenteral Support

Protara Therapeutics Receives Both FDA Breakthrough Therapy and Fast Track Designations for TARA-002 in Pediatric Patients with Lymphatic Malformations

Protara Announces Closing of $75 Million Public Offering

Protara Announces Pricing of $75 Million Public Offering